Skip to main content

DGX Quest Diagnostics Incorporated

Healthcare

250.81 -1.01 -0.40% Close 11/2
Since 2024-12-02 +61.5%
Open
251.60
High
251.98
Low
247.71
Prev close
251.82
Volume
996.1K
Amplitude
1.70%
P/E
25.1
P/B
3.6
Revenue YoY (TTM)
+9.1%
52W 171.18 256.99

Is Quest Diagnostics Incorporated a buy? Fundamentals and valuation first

As of 2026-10-30

Quality: Good, Growth: Good, Momentum: Strong, Risk / liquidity: Strong; Valuation: Pricey.

Valuation Pricey Free-cash-flow yield is Good, but Price / book is Pricey.
TTM P/E 25.08 62th percentile Pricey
Price / book 3.63 76th percentile Pricey
Free-cash-flow yield (%) 4.96 67th percentile Good
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Good All 3 indicators are Good.
ROE, TTM (%) 14.79 75th percentile Good
Operating margin, TTM (%) 14.59 64th percentile Good
FCF margin, TTM (%) 11.61 64th percentile Good
Quality Factor Investing: A US Quality Value Backtest
Growth Good All 2 indicators are Good.
Revenue growth, TTM YoY (%) 9.13 59th percentile Good
Diluted EPS growth, TTM YoY (%) 17.84 65th percentile Good
Momentum Strong All 2 indicators are Top.
60-day return (%) 5.98 82th percentile Top
240-day return (%) 36.96 82th percentile Top
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Strong 20-day dollar volume is Top; 60-day annualized volatility is Good.
20-day dollar volume 246,294,139 94th percentile Top
60-day annualized volatility (%) 20.88 23th percentile Good
Factor Investing Explained: 10 Classic Factors in US Stocks

Quest Diagnostics Incorporated (DGX) today

2 quant signals active · As of 2026-10-30

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

FinLab Studio

From Quest Diagnostics Incorporated to every stock like it

AI finds several complementary traits of Quest Diagnostics Incorporated across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like Quest Diagnostics Incorporated

Quest Diagnostics Incorporated (DGX) peers and tracking

Watchlist

This page refreshes daily after the close. Add Quest Diagnostics Incorporated to your watchlist to track signal changes on your next visit.

Quest Diagnostics Incorporated (DGX) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

31 historical occurrences (since 2017-01-04)

Average forward return after 52-week adjusted-price high

20-day: Win 46.7%, Sample 30, Median -0.13%, Excess -1.92%, Beat mkt rate 40%

60-day: Win 69%, Sample 29, Median +2.5%, Excess -2.22%, Beat mkt rate 41.4%

120-day: Win 77.8%, Sample 27, Median +5.47%, Excess -1.48%, Beat mkt rate 51.9%

120 days after: historical avg +4.9%

20-day +0.14%
60-day +0.81%
120-day +4.9%
20-day
60-day
120-day
Win
46.7%
69%
77.8%
Sample
30
29
27
Median
-0.13%
+2.5%
+5.47%
Excess
-1.92%
-2.22%
-1.48%
Beat mkt rate
40%
41.4%
51.9%

Over 27 occurrences, 120-day forward avg gained 4.9%, lagged the market by 1.48 pts; win rate 77.8%.

Top-quintile 6-month momentum

Active · now 84.8%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest
15 historical occurrences (since 2016-08-03)

Average forward return after Top-quintile 6-month momentum

20-day: Win 64.3%, Sample 14, Median +1.6%, Excess -2.59%, Beat mkt rate 50%

60-day: Win 64.3%, Sample 14, Median +2.81%, Excess -4.74%, Beat mkt rate 0%

120-day: Win 69.2%, Sample 13, Median +2.81%, Excess -10.03%, Beat mkt rate 30.8%

120 days after: historical avg +0.37%

20-day -0.61%
60-day +1.16%
120-day +0.37%
20-day
60-day
120-day
Win
64.3%
64.3%
69.2%
Sample
14
14
13
Median
+1.6%
+2.81%
+2.81%
Excess
-2.59%
-4.74%
-10.03%
Beat mkt rate
50%
0%
30.8%

Over 13 occurrences, 120-day forward avg gained 0.37%, lagged the market by 10.03 pts; win rate 69.2%.

Valuation regime and forward returns

Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 458+8.3% +6.7% 67.7% +3.7%
20-40 156-0.1% -1.8% 43.6% -17.4%
40-60 205+18.8% +25.4% 72.7% -2.9%
60-80 227+20.2% +19.4% 98.2% -2.1%
80-100 You are here379+18.4% +18.1% 96.8% -2%

Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.

Current TTM P/E is about 25.08, placing it in the 98.7 own-history percentile, inside the 80-100 bucket.

More history: Valuation × momentum analogs, Market-wide momentum baseline, Signals not active now

Valuation × momentum analogs

Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.

Valuation
Momentum
Cheap (own-history bottom third)
Middle
Expensive (own-history top third)
60-day momentum up
+5.2%
Win rate 69.2% Excess +1.1%
338d
+2.7%
Win rate 53.8% Excess -8.7%
158d
Now
+8.7%
Win rate 92.2% Excess -0.7%
539d
60-day momentum down
+9.6%
Win rate 69.4% Excess +6.1%
209d
+7.1%
Win rate 66.9% Excess -5.1%
160d
+7.8%
Win rate 81.6% Excess -1.1%
141d

Currently in “Expensive (own-history top third) × 60-day momentum up”: across 539 historical days, 120-day forward avg gained 8.7%, win rate 92.2%, lagged the market by 0.7%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Market-wide momentum baseline

Across 99,493 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.42%, a 58.4% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

5 times historically; 60-day forward avg +6.86%, win rate 100%, beating the market by +3.08 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest

12 times historically; 60-day forward avg +3.96%, win rate 75%, beating the market by -1.04 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.